RecruitingNCT05337631

Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy

Sponsor

University Hospital Freiburg

Enrollment

1,500 participants

Start Date

Jun 1, 2021

Study Type

OBSERVATIONAL

Conditions

HNSCC Oral Cavity Cancer Oropharynx Cancer Larynx Cancer Hypopharynx Cancer

Summary

The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and alternative chemotherapy fractionation (e.g., cisplatin weekly) may have altered this observation. The objective of this retrospective multinational multicenter study is to determine the oncological outcomes of elderly patients (≥65 years) with locally advanced HNSCCs undergoing definitive (chemo-)radiation and to investigate the influence of concomitant chemotherapy on overall survival and progression-free survival after adjusting for potential confounder variables such as age, performance status and comorbidity burden.

Eligibility

Min Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is reviewing how elderly patients (65+) with head and neck cancer were managed during radiation treatment, to better understand what special care approaches work best for this age group. **You may be eligible if...** - You are 65 years or older at the time of treatment - You have locally advanced squamous cell carcinoma of the oral cavity, throat (oropharynx, hypopharynx), or voice box (larynx) - You received radiation therapy (with or without chemotherapy) as your main treatment since 2005 **You may NOT be eligible if...** - You received radiation as a follow-up after surgery (adjuvant therapy) - You had a previous head and neck cancer or prior radiation to the head/neck area - You had distant metastases (cancer spread to other organs) at the start of treatment - Your cancer was in the nasopharynx, salivary glands, or skin Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(18)

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine

Baltimore, Maryland, United States

Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai

New York, New York, United States

Department of Radiation Oncology, Case Western Reserve University

Cleveland, Ohio, United States

Division of Radiation Oncology, The Ohio State University Wexner

Columbus, Ohio, United States

Radiation Oncology Department, German Oncology Center

Limassol, Cyprus

Brno University Hospital

Brno, Czechia

Department of Radiooncology and Radiotherapy, Charité-Universitätsmedizin Berlin

Berlin, Germany

Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg

Erlangen, Germany

Department of Radiotherapy and Oncology, Goethe-University Frankfurt am Main

Frankfurt, Germany

University of Giessen

Giessen, Germany

Martin-Luther-Universität Halle-Wittenberg

Halle, Germany

Jena University Hospital

Jena, Germany

Department of Radiation Oncology, University Hospital Schleswig-Holstein

Kiel, Germany

Department of Radiation Oncology, University Medical Center Leipzig

Leipzig, Germany

Department of Radiation Oncology, University Medical Center Mainz

Mainz, Germany

Department of Radiation Oncology, University Hospital, LMU Munich

Munich, Germany

Department of Radiation Oncology, University Hospital Würzburg

Würzburg, Germany

Department of Radiation Oncology, University Hospital Zurich (USZ), University of Zurich (UZH)

Zurich, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05337631

Related Trials

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

NCT069970681 location

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

NCT061902751 location

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

NCT041141361 location

Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

NCT067064018 locations

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

NCT072091891 location